🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

Cases of gonorrhoea are increasing worldwide, with figures suggesting over 82 million instances annually. Notably increased rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune step in the reality of rising global incidence, escalating drug resistance and the very limited therapeutic options presently on offer.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "critical concern". A tracking program found that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Clearance

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in close succession. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

According to data detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This puts it on an equal footing with the current standard treatment, which combines a dual-drug approach. The trial included hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the authority to license and sell the drug in many developing nations.

Clinicians treating patients have shared positive views. Having a single-dose, oral treatment like this is seen as a "game-changer" for managing the epidemic. This is viewed as crucial to alleviate the strain of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea around the world.